144 related articles for article (PubMed ID: 38061370)
1. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.
Ray KK; Nicholls SJ; Li N; Louie MJ; Brennan D; Lincoff AM; Nissen SE;
Lancet Diabetes Endocrinol; 2024 Jan; 12(1):19-28. PubMed ID: 38061370
[TBL] [Abstract][Full Text] [Related]
2. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE; Lincoff AM; Brennan D; Ray KK; Mason D; Kastelein JJP; Thompson PD; Libby P; Cho L; Plutzky J; Bays HE; Moriarty PM; Menon V; Grobbee DE; Louie MJ; Chen CF; Li N; Bloedon L; Robinson P; Horner M; Sasiela WJ; McCluskey J; Davey D; Fajardo-Campos P; Petrovic P; Fedacko J; Zmuda W; Lukyanov Y; Nicholls SJ;
N Engl J Med; 2023 Apr; 388(15):1353-1364. PubMed ID: 36876740
[TBL] [Abstract][Full Text] [Related]
3. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
[TBL] [Abstract][Full Text] [Related]
4. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK; Colhoun HM; Szarek M; Baccara-Dinet M; Bhatt DL; Bittner VA; Budaj AJ; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Lopes RD; Moryusef A; Murin J; Pordy R; Ristic AD; Roe MT; Tuñón J; White HD; Zeiher AM; Schwartz GG; Steg PG;
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):618-628. PubMed ID: 31272931
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Sabatine MS; Leiter LA; Wiviott SD; Giugliano RP; Deedwania P; De Ferrari GM; Murphy SA; Kuder JF; Gouni-Berthold I; Lewis BS; Handelsman Y; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR
Lancet Diabetes Endocrinol; 2017 Dec; 5(12):941-950. PubMed ID: 28927706
[TBL] [Abstract][Full Text] [Related]
6. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials.
Leiter LA; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Mancini GBJ; Ray KK; Hanselman JC; Ye Z; Bays HE
Diabetes Obes Metab; 2022 May; 24(5):868-880. PubMed ID: 34981622
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.
Inzucchi SE; Claggett BL; Vaduganathan M; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Verma S; Han Y; Kerr Saraiva JF; Bengtsson O; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Lancet Diabetes Endocrinol; 2022 Dec; 10(12):869-881. PubMed ID: 36372069
[TBL] [Abstract][Full Text] [Related]
9. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
Ridker PM; Lei L; Louie MJ; Haddad T; Nicholls SJ; Lincoff AM; Libby P; Nissen SE;
Circulation; 2024 Jan; 149(1):28-35. PubMed ID: 37929602
[TBL] [Abstract][Full Text] [Related]
10. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.
Nissen SE; Menon V; Nicholls SJ; Brennan D; Laffin L; Ridker P; Ray KK; Mason D; Kastelein JJP; Cho L; Libby P; Li N; Foody J; Louie MJ; Lincoff AM
JAMA; 2023 Jul; 330(2):131-140. PubMed ID: 37354546
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
[TBL] [Abstract][Full Text] [Related]
12. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
[TBL] [Abstract][Full Text] [Related]
13. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
[TBL] [Abstract][Full Text] [Related]
14. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
15. Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant.
Doggrell SA
Expert Opin Pharmacother; 2023; 24(15):1673-1677. PubMed ID: 37496276
[TBL] [Abstract][Full Text] [Related]
16. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
Bays HE; Bloedon LT; Lin G; Powell HA; Louie MJ; Nicholls SJ; Lincoff AM; Nissen SE
J Clin Lipidol; 2024; 18(1):e59-e69. PubMed ID: 37951797
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
Nicholls S; Lincoff AM; Bays HE; Cho L; Grobbee DE; Kastelein JJ; Libby P; Moriarty PM; Plutzky J; Ray KK; Thompson PD; Sasiela W; Mason D; McCluskey J; Davey D; Wolski K; Nissen SE
Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
[TBL] [Abstract][Full Text] [Related]
18. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
Duarte Lau F; Giugliano RP
JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
[TBL] [Abstract][Full Text] [Related]
20. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
